These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26571380)

  • 1. Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
    Fraveto A; Cardinale V; Bragazzi MC; Giuliante F; De Rose AM; Grazi GL; Napoletano C; Semeraro R; Lustri AM; Costantini D; Nevi L; Di Matteo S; Renzi A; Carpino G; Gaudio E; Alvaro D
    PLoS One; 2015; 10(11):e0142124. PubMed ID: 26571380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
    Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
    PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
    Zhu HQ; Ma JB; Song X; Gao HJ; Ma CQ; Chang H; Li HG; Liu FF; Lu J; Zhou X
    Oncol Rep; 2016 Dec; 36(6):3488-3496. PubMed ID: 27779693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models.
    Awasthi N; Darman L; Schwarz MA; Schwarz RE
    J Cell Mol Med; 2024 Sep; 28(17):e18585. PubMed ID: 39223878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
    Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
    Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma.
    Braconi C; Swenson E; Kogure T; Huang N; Patel T
    PLoS One; 2010 Dec; 5(12):e15195. PubMed ID: 21179572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
    Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 17. Blocking of methionine aminopeptidase-2 by TNP-470 induces apoptosis and increases chemosensitivity of cholangiocarcinoma.
    Kidoikhammouan S; Seubwai W; Silsirivanit A; Wongkham S; Sawanyawisuth K; Wongkham C
    J Cancer Res Ther; 2019; 15(1):148-152. PubMed ID: 30880771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
    Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE
    Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice].
    Wu T; Jiang X; Xu B; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1448-1456. PubMed ID: 33118510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.